Compare C3.ai Inc (AI) vs 10X Genomics Inc (TXG) Price & Performance

C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.

While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.

TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.

The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.